Skip to main content
Enter your The Contraceptive Pipeline Database username.
Enter the password that accompanies your username.
Nestorone (NES) + Estradiol (E2) Transdermal Gel
Proprietary gel technology (Antares ATD™ technology) of a hydroalcoholic gel combined with permeation enhancers to deliver Nestorone and Estradiol through the skin. The gel is administered by an airless, pre-filled metered dose pump dispenser.
May 30, 2018
Active Pharmaceutical Ingredient (API):
Potential Multi-Purpose Technology (MPT):
Nestorone 3mg/day; E2 1mg/day per daily dose; 10% absorbed
Phase 1 and 2 clinical trials have been conducted in Chile, the Dominican Republic, and the USA. An Investigational New Drug (IND) application was submitted to the FDA in 2008, and outcomes from the dose-finding study were used to support registration of a new patent.
Results from a small qualitative study suggest women highly satisfied with this method.
Likely increased flexibility in timing for daily doses compared to oral contraceptives; clinical trials suggest elimination half-life of approximately 72 hours. Transdermal gel would require daily administration.
Population Council website
Download Product Report